THE NEXT GENERATION OF IMMUNOTHERAPY
Immunovative Therapies, Ltd. is a clinical stage Israeli biopharmaceutical company specializing in the translation of proven immune mechanisms into immunotherapy products and protocols for treatment of cancer and infectious diseases. Our patented “Mirror EffectTM” technology provides an immunological platform for the development of drugs that elicit the same powerful anti-tumor and anti-HIV effects of bone marrow/stem cell transplant procedures while eliminating the devastating side effects of the procedure and the need for a tissue matched donor. We have two products in clinical development: AlloStim®, a bioengineered living cell allograft; and Chaperone-Rich Cell Lysate (CRCL), a patient-specific heat shock protein vaccine. AlloStim combines with a tumor cryoablation (killing by freezing) method to create an in-situ cancer vaccine called CryoVaxTM and combines with CRCL to create a personalized cancer vaccine called AlloVaxTM.
Immunovative is the Future of Immunotherapy
Immunovative is the Future of Immunotherapy

CONTROLLING IMMUNE NETWORKS
CONTROLLING IMMUNE NETWORKS


SPECIALITY INFORMATION
patients

No requirement for a matched donor or chemotherapy/radiation conditioning prior to treatment.
Innovative technology – proven and non-toxic.
read more
Healthcare professionals

Elicits a GVT-like mechanism without the GVHD toxicity.
read more
Investors

Over 200 individual private shareholders and grant support from the Israel Office of the Chief Scientist.
read more